APO Research
Talk to an analyst

APO RESEARCH · REPORT

In-Vitro Cancer Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global In-Vitro Cancer Diagnostics Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchIn-Vitro Cancer Diagnostics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal In-Vitro Cancer Diagnostics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal In-Vitro Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In-Vitro Cancer Diagnostics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal In-Vitro Cancer Diagnostics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global In-Vitro Cancer Diagnostics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for In-Vitro Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for In-Vitro Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for In-Vitro Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for In-Vitro Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of In-Vitro Cancer Diagnostics include Abbott Laboratories, Beckman Coulter, Epigenomics AG, MDx Health Quest Diagnostics, Randox Laboratories, R-Biopharm AG, Signature Diagnostics, Amoy Diagnostics Co.,Ltd. and Daan Gene, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for In-Vitro Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of In-Vitro Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for In-Vitro Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the In-Vitro Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global In-Vitro Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for In-Vitro Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

In-Vitro Cancer Diagnostics Segment by Company

Abbott Laboratories

Beckman Coulter

Epigenomics AG

MDx Health Quest Diagnostics

Randox Laboratories

R-Biopharm AG

Signature Diagnostics

Amoy Diagnostics Co.,Ltd.

Daan Gene

Fosun Pharma

Novogene

Burning Rock

Geneseeq

Siemens Healthcare

In-Vitro Cancer Diagnostics Segment by Type

Instruments

Reagents and Kits

In-Vitro Cancer Diagnostics Segment by Application

Laboratories

Hospitals

Others

In-Vitro Cancer Diagnostics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In-Vitro Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In-Vitro Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In-Vitro Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of In-Vitro Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of In-Vitro Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, In-Vitro Cancer Diagnostics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global In-Vitro Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Instruments Major Player Table 3. Reagents and Kits Major Player Table 4. Global In-Vitro Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Laboratories Major Player Table 6. Hospitals Major Player Table 7. Others Major Player Table 8. In-Vitro Cancer Diagnostics Industry Trends Table 9. In-Vitro Cancer Diagnostics Industry Drivers Table 10. In-Vitro Cancer Diagnostics Industry Opportunities and Challenges Table 11. In-Vitro Cancer Diagnostics Industry Restraints Table 12. Global In-Vitro Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global In-Vitro Cancer Diagnostics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global In-Vitro Cancer Diagnostics Market Share by Region (2021-2026) Table 15. Global In-Vitro Cancer Diagnostics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global In-Vitro Cancer Diagnostics Market Share by Region (2027-2032) Table 17. Global In-Vitro Cancer Diagnostics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global In-Vitro Cancer Diagnostics Revenue Market Share by Players (2021-2026) Table 19. Global In-Vitro Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global In-Vitro Cancer Diagnostics Key Players Headquarters & Area Served Table 21. Global In-Vitro Cancer Diagnostics Players, Product Type & Application Table 22. Global In-Vitro Cancer Diagnostics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global In-Vitro Cancer Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global In-Vitro Cancer Diagnostics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global In-Vitro Cancer Diagnostics Revenue Market Share by Type (2021-2026) Table 29. Global In-Vitro Cancer Diagnostics Revenue Market Share by Type (2027-2032) Table 30. Global In-Vitro Cancer Diagnostics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global In-Vitro Cancer Diagnostics Revenue Market Share by Application (2021-2026) Table 34. Global In-Vitro Cancer Diagnostics Revenue Market Share by Application (2027-2032) Table 35. Abbott Laboratories Company Information Table 36. Abbott Laboratories Business Overview Table 37. Abbott Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Abbott Laboratories In-Vitro Cancer Diagnostics Product Portfolio Table 39. Abbott Laboratories Recent Development Table 40. Beckman Coulter Company Information Table 41. Beckman Coulter Business Overview Table 42. Beckman Coulter In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Beckman Coulter In-Vitro Cancer Diagnostics Product Portfolio Table 44. Beckman Coulter Recent Development Table 45. Epigenomics AG Company Information Table 46. Epigenomics AG Business Overview Table 47. Epigenomics AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Epigenomics AG In-Vitro Cancer Diagnostics Product Portfolio Table 49. Epigenomics AG Recent Development Table 50. MDx Health Quest Diagnostics Company Information Table 51. MDx Health Quest Diagnostics Business Overview Table 52. MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Product Portfolio Table 54. MDx Health Quest Diagnostics Recent Development Table 55. Randox Laboratories Company Information Table 56. Randox Laboratories Business Overview Table 57. Randox Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Randox Laboratories In-Vitro Cancer Diagnostics Product Portfolio Table 59. Randox Laboratories Recent Development Table 60. R-Biopharm AG Company Information Table 61. R-Biopharm AG Business Overview Table 62. R-Biopharm AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. R-Biopharm AG In-Vitro Cancer Diagnostics Product Portfolio Table 64. R-Biopharm AG Recent Development Table 65. Signature Diagnostics Company Information Table 66. Signature Diagnostics Business Overview Table 67. Signature Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Signature Diagnostics In-Vitro Cancer Diagnostics Product Portfolio Table 69. Signature Diagnostics Recent Development Table 70. Amoy Diagnostics Co.,Ltd. Company Information Table 71. Amoy Diagnostics Co.,Ltd. Business Overview Table 72. Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Product Portfolio Table 74. Amoy Diagnostics Co.,Ltd. Recent Development Table 75. Daan Gene Company Information Table 76. Daan Gene Business Overview Table 77. Daan Gene In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Daan Gene In-Vitro Cancer Diagnostics Product Portfolio Table 79. Daan Gene Recent Development Table 80. Fosun Pharma Company Information Table 81. Fosun Pharma Business Overview Table 82. Fosun Pharma In-Vitro Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Fosun Pharma In-Vitro Cancer Diagnostics Product Portfolio Table 84. Fosun Pharma Recent Development Table 85. Novogene Company Information Table 86. Novogene Business Overview Table 87. Novogene In-Vitro Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Novogene In-Vitro Cancer Diagnostics Product Portfolio Table 89. Novogene Recent Development Table 90. Burning Rock Company Information Table 91. Burning Rock Business Overview Table 92. Burning Rock In-Vitro Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Burning Rock In-Vitro Cancer Diagnostics Product Portfolio Table 94. Burning Rock Recent Development Table 95. Geneseeq Company Information Table 96. Geneseeq Business Overview Table 97. Geneseeq In-Vitro Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Geneseeq In-Vitro Cancer Diagnostics Product Portfolio Table 99. Geneseeq Recent Development Table 100. Siemens Healthcare Company Information Table 101. Siemens Healthcare Business Overview Table 102. Siemens Healthcare In-Vitro Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Siemens Healthcare In-Vitro Cancer Diagnostics Product Portfolio Table 104. Siemens Healthcare Recent Development Table 105. North America In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 106. North America In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 107. North America In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 108. North America In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 109. North America In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America In-Vitro Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 111. North America In-Vitro Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe In-Vitro Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe In-Vitro Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 119. China In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 120. China In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 121. China In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 122. China In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia In-Vitro Cancer Diagnostics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia In-Vitro Cancer Diagnostics Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia In-Vitro Cancer Diagnostics Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA In-Vitro Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA In-Vitro Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA In-Vitro Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA In-Vitro Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA In-Vitro Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA In-Vitro Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. In-Vitro Cancer Diagnostics Image Figure 2. Global In-Vitro Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global In-Vitro Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Instruments Image Figure 5. Reagents and Kits Image Figure 6. Global In-Vitro Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global In-Vitro Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Laboratories Image Figure 9. Hospitals Image Figure 10. Others Image Figure 11. Global In-Vitro Cancer Diagnostics Market Size (US$ Million) & (2021-2032) Figure 12. Global In-Vitro Cancer Diagnostics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global In-Vitro Cancer Diagnostics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global In-Vitro Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global In-Vitro Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global In-Vitro Cancer Diagnostics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global In-Vitro Cancer Diagnostics Revenue Market Share by Type (2021-2032) Figure 19. Global In-Vitro Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global In-Vitro Cancer Diagnostics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global In-Vitro Cancer Diagnostics Revenue Market Share by Application (2021-2032) Figure 22. North America In-Vitro Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 24. North America In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 25. North America In-Vitro Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 26. United States In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe In-Vitro Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 31. Europe In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 32. Europe In-Vitro Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 33. Germany In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China In-Vitro Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 43. China In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 44. Asia In-Vitro Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 46. Asia In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 47. Asia In-Vitro Cancer Diagnostics Revenue Share by Region (2021-2032) Figure 48. Japan In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA In-Vitro Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 56. SAMEA In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 57. SAMEA In-Vitro Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 58. Brazil In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt In-Vitro Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Kits
Applications
  • Laboratories
  • Hospitals
  • Others
Companies covered
  • Abbott Laboratories
  • Beckman Coulter
  • Epigenomics AG
  • MDx Health Quest Diagnostics
  • Randox Laboratories
  • R-Biopharm AG
  • Signature Diagnostics
  • Amoy Diagnostics Co.,Ltd.
  • Daan Gene
  • Fosun Pharma
  • Novogene
  • Burning Rock
  • Geneseeq
  • Siemens Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 In-Vitro Cancer Diagnostics Market by Type
  3. 1.2.1 Global In-Vitro Cancer Diagnostics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Instruments
  5. 1.2.3 Reagents and Kits
  6. 1.3 In-Vitro Cancer Diagnostics Market by Application
  7. 1.3.1 Global In-Vitro Cancer Diagnostics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Laboratories
  9. 1.3.3 Hospitals
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 In-Vitro Cancer Diagnostics Market Dynamics
  1. 2.1 In-Vitro Cancer Diagnostics Industry Trends
  2. 2.2 In-Vitro Cancer Diagnostics Industry Drivers
  3. 2.3 In-Vitro Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 In-Vitro Cancer Diagnostics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global In-Vitro Cancer Diagnostics Market Perspective (2021-2032)
  2. 3.2 Global In-Vitro Cancer Diagnostics Growth Trends by Region
  3. 3.2.1 Global In-Vitro Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global In-Vitro Cancer Diagnostics Market Size by Region (2021-2026)
  5. 3.2.3 Global In-Vitro Cancer Diagnostics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global In-Vitro Cancer Diagnostics Revenue by Players
  2. 4.1.1 Global In-Vitro Cancer Diagnostics Revenue by Players (2021-2026)
  3. 4.1.2 Global In-Vitro Cancer Diagnostics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global In-Vitro Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global In-Vitro Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global In-Vitro Cancer Diagnostics Key Players Headquarters & Area Served
  7. 4.4 Global In-Vitro Cancer Diagnostics Players, Product Type & Application
  8. 4.5 Global In-Vitro Cancer Diagnostics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global In-Vitro Cancer Diagnostics Market CR5 and HHI
  11. 4.6.3 2025 In-Vitro Cancer Diagnostics Tier 1, Tier 2, and Tier 3
5 In-Vitro Cancer Diagnostics Market Size by Type
  1. 5.1 Global In-Vitro Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 5.3 Global In-Vitro Cancer Diagnostics Revenue Market Share by Type (2021-2032)
6 In-Vitro Cancer Diagnostics Market Size by Application
  1. 6.1 Global In-Vitro Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  3. 6.3 Global In-Vitro Cancer Diagnostics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott Laboratories
  2. 7.1.1 Abbott Laboratories Company Information
  3. 7.1.2 Abbott Laboratories Business Overview
  4. 7.1.3 Abbott Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Laboratories In-Vitro Cancer Diagnostics Product Portfolio
  6. 7.1.5 Abbott Laboratories Recent Developments
  7. 7.2 Beckman Coulter
  8. 7.2.1 Beckman Coulter Company Information
  9. 7.2.2 Beckman Coulter Business Overview
  10. 7.2.3 Beckman Coulter In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Beckman Coulter In-Vitro Cancer Diagnostics Product Portfolio
  12. 7.2.5 Beckman Coulter Recent Developments
  13. 7.3 Epigenomics AG
  14. 7.3.1 Epigenomics AG Company Information
  15. 7.3.2 Epigenomics AG Business Overview
  16. 7.3.3 Epigenomics AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Epigenomics AG In-Vitro Cancer Diagnostics Product Portfolio
  18. 7.3.5 Epigenomics AG Recent Developments
  19. 7.4 MDx Health Quest Diagnostics
  20. 7.4.1 MDx Health Quest Diagnostics Company Information
  21. 7.4.2 MDx Health Quest Diagnostics Business Overview
  22. 7.4.3 MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
  24. 7.4.5 MDx Health Quest Diagnostics Recent Developments
  25. 7.5 Randox Laboratories
  26. 7.5.1 Randox Laboratories Company Information
  27. 7.5.2 Randox Laboratories Business Overview
  28. 7.5.3 Randox Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Randox Laboratories In-Vitro Cancer Diagnostics Product Portfolio
  30. 7.5.5 Randox Laboratories Recent Developments
  31. 7.6 R-Biopharm AG
  32. 7.6.1 R-Biopharm AG Company Information
  33. 7.6.2 R-Biopharm AG Business Overview
  34. 7.6.3 R-Biopharm AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 R-Biopharm AG In-Vitro Cancer Diagnostics Product Portfolio
  36. 7.6.5 R-Biopharm AG Recent Developments
  37. 7.7 Signature Diagnostics
  38. 7.7.1 Signature Diagnostics Company Information
  39. 7.7.2 Signature Diagnostics Business Overview
  40. 7.7.3 Signature Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Signature Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
  42. 7.7.5 Signature Diagnostics Recent Developments
  43. 7.8 Amoy Diagnostics Co.,Ltd.
  44. 7.8.1 Amoy Diagnostics Co.,Ltd. Company Information
  45. 7.8.2 Amoy Diagnostics Co.,Ltd. Business Overview
  46. 7.8.3 Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Product Portfolio
  48. 7.8.5 Amoy Diagnostics Co.,Ltd. Recent Developments
  49. 7.9 Daan Gene
  50. 7.9.1 Daan Gene Company Information
  51. 7.9.2 Daan Gene Business Overview
  52. 7.9.3 Daan Gene In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Daan Gene In-Vitro Cancer Diagnostics Product Portfolio
  54. 7.9.5 Daan Gene Recent Developments
  55. 7.10 Fosun Pharma
  56. 7.10.1 Fosun Pharma Company Information
  57. 7.10.2 Fosun Pharma Business Overview
  58. 7.10.3 Fosun Pharma In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Fosun Pharma In-Vitro Cancer Diagnostics Product Portfolio
  60. 7.10.5 Fosun Pharma Recent Developments
  61. 7.11 Novogene
  62. 7.11.1 Novogene Company Information
  63. 7.11.2 Novogene Business Overview
  64. 7.11.3 Novogene In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novogene In-Vitro Cancer Diagnostics Product Portfolio
  66. 7.11.5 Novogene Recent Developments
  67. 7.12 Burning Rock
  68. 7.12.1 Burning Rock Company Information
  69. 7.12.2 Burning Rock Business Overview
  70. 7.12.3 Burning Rock In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Burning Rock In-Vitro Cancer Diagnostics Product Portfolio
  72. 7.12.5 Burning Rock Recent Developments
  73. 7.13 Geneseeq
  74. 7.13.1 Geneseeq Company Information
  75. 7.13.2 Geneseeq Business Overview
  76. 7.13.3 Geneseeq In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Geneseeq In-Vitro Cancer Diagnostics Product Portfolio
  78. 7.13.5 Geneseeq Recent Developments
  79. 7.14 Siemens Healthcare
  80. 7.14.1 Siemens Healthcare Company Information
  81. 7.14.2 Siemens Healthcare Business Overview
  82. 7.14.3 Siemens Healthcare In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Siemens Healthcare In-Vitro Cancer Diagnostics Product Portfolio
  84. 7.14.5 Siemens Healthcare Recent Developments
8 North America
  1. 8.1 North America In-Vitro Cancer Diagnostics Revenue (2021-2032)
  2. 8.2 North America In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 8.2.1 North America In-Vitro Cancer Diagnostics Revenue by Type (2021-2026)
  4. 8.2.2 North America In-Vitro Cancer Diagnostics Revenue by Type (2027-2032)
  5. 8.3 North America In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 8.4 North America In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  7. 8.4.1 North America In-Vitro Cancer Diagnostics Revenue by Application (2021-2026)
  8. 8.4.2 North America In-Vitro Cancer Diagnostics Revenue by Application (2027-2032)
  9. 8.5 North America In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 8.6 North America In-Vitro Cancer Diagnostics Revenue by Country
  11. 8.6.1 North America In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America In-Vitro Cancer Diagnostics Revenue by Country (2021-2026)
  13. 8.6.3 North America In-Vitro Cancer Diagnostics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe In-Vitro Cancer Diagnostics Revenue (2021-2032)
  2. 9.2 Europe In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 9.2.1 Europe In-Vitro Cancer Diagnostics Revenue by Type (2021-2026)
  4. 9.2.2 Europe In-Vitro Cancer Diagnostics Revenue by Type (2027-2032)
  5. 9.3 Europe In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 9.4 Europe In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  7. 9.4.1 Europe In-Vitro Cancer Diagnostics Revenue by Application (2021-2026)
  8. 9.4.2 Europe In-Vitro Cancer Diagnostics Revenue by Application (2027-2032)
  9. 9.5 Europe In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 9.6 Europe In-Vitro Cancer Diagnostics Revenue by Country
  11. 9.6.1 Europe In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe In-Vitro Cancer Diagnostics Revenue by Country (2021-2026)
  13. 9.6.3 Europe In-Vitro Cancer Diagnostics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China In-Vitro Cancer Diagnostics Revenue (2021-2032)
  2. 10.2 China In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 10.2.1 China In-Vitro Cancer Diagnostics Revenue by Type (2021-2026)
  4. 10.2.2 China In-Vitro Cancer Diagnostics Revenue by Type (2027-2032)
  5. 10.3 China In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 10.4 China In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  7. 10.4.1 China In-Vitro Cancer Diagnostics Revenue by Application (2021-2026)
  8. 10.4.2 China In-Vitro Cancer Diagnostics Revenue by Application (2027-2032)
  9. 10.5 China In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia In-Vitro Cancer Diagnostics Revenue (2021-2032)
  2. 11.2 Asia In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 11.2.1 Asia In-Vitro Cancer Diagnostics Revenue by Type (2021-2026)
  4. 11.2.2 Asia In-Vitro Cancer Diagnostics Revenue by Type (2027-2032)
  5. 11.3 Asia In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 11.4 Asia In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  7. 11.4.1 Asia In-Vitro Cancer Diagnostics Revenue by Application (2021-2026)
  8. 11.4.2 Asia In-Vitro Cancer Diagnostics Revenue by Application (2027-2032)
  9. 11.5 Asia In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 11.6 Asia In-Vitro Cancer Diagnostics Revenue by Country
  11. 11.6.1 Asia In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia In-Vitro Cancer Diagnostics Revenue by Country (2021-2026)
  13. 11.6.3 Asia In-Vitro Cancer Diagnostics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA In-Vitro Cancer Diagnostics Revenue (2021-2032)
  2. 12.2 SAMEA In-Vitro Cancer Diagnostics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA In-Vitro Cancer Diagnostics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA In-Vitro Cancer Diagnostics Revenue by Type (2027-2032)
  5. 12.3 SAMEA In-Vitro Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA In-Vitro Cancer Diagnostics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA In-Vitro Cancer Diagnostics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA In-Vitro Cancer Diagnostics Revenue by Application (2027-2032)
  9. 12.5 SAMEA In-Vitro Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA In-Vitro Cancer Diagnostics Revenue by Country
  11. 12.6.1 SAMEA In-Vitro Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA In-Vitro Cancer Diagnostics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA In-Vitro Cancer Diagnostics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst